The Company is a Korea-based company principally engaged in the drug delivery system development and sale business. The Company focus on researching and developing of ultrasound-guided therapy technology which utilizes ultrasound and nanoparticle technology. The Company provides IMGT-LPS, IMGT-EMB and IMGT-TSD technologies. IMGT-LPS technology injects ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances into body and releases drugs by irradiating ultrasound to the target area. IMGT-EMB is a nanoparticle for chemoembolization of liver cancer and can be injected into cancer area in form of emulsion. IMGT-TSD is a targeted sonodynamic therapy induces immune boosting mechanism by applying ultrasonic stimulation to the cancer area. In addition, the Company engages in the non-invasive treatment devices IMGT-FUS which using focused ultrasound technology. The Company was established on April 5, 2010. The Company share was listed on the KONEX on July 19, 2023.
Headquarters
172, Dolma-Ro, Bundang-Gu
Seongnam; Gyeonggi;
Contact Details: Purchase the Imgt Corporation Ltd. report to view the information.
Website: http://www.imgt.co.kr/
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service